List of Excipients in Branded Drug ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE

Generic Drugs Containing ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	orphenadrine citrate, aspirin and caffeine	21695-726	ANHYDROUS LACTOSE
Rebel Distributors Corp	orphenadrine citrate, aspirin and caffeine	21695-726	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	orphenadrine citrate, aspirin and caffeine	21695-726	CROSCARMELLOSE SODIUM
Rebel Distributors Corp	orphenadrine citrate, aspirin and caffeine	21695-726	D&C YELLOW NO. 10
Rebel Distributors Corp	orphenadrine citrate, aspirin and caffeine	21695-726	FD&C BLUE NO. 1
Rebel Distributors Corp	orphenadrine citrate, aspirin and caffeine	21695-726	POVIDONE

What are the Most Frequently-Used Excipients in ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE?

# Of NDCs	Excipient
4	ANHYDROUS LACTOSE
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
4	D&C YELLOW NO. 10
4	FD&C BLUE NO. 1
4	POVIDONE

Orphenadrine Citrate, Aspirin and Caffeine: Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Orphenadrine citrate, aspirin and caffeine is an established prescription combination used for painful musculoskeletal conditions. The best commercial opportunities are generic or reformulated immediate-release tablets, with differentiation based on stability, tablet size, manufacturing efficiency, packaging, and patient tolerability. The combination has limited biologic or biosimilar risk and is unlikely to support meaningful exclusivity through the active ingredients alone. New protection would need to come from a technically credible formulation, manufacturing process, dosage form, or clinical-use innovation.

What is the orphenadrine citrate, aspirin and caffeine combination?

The combination contains:

Component	Pharmacologic role	Formulation relevance
Orphenadrine citrate	Centrally acting skeletal-muscle relaxant with anticholinergic activity	Low-dose content requires strong blend-uniformity controls
Aspirin	Analgesic and anti-inflammatory salicylate	Sensitive to moisture and hydrolysis; can affect tablet stability
Caffeine	Analgesic adjuvant and stimulant	Low dose, crystalline material; contributes to blend segregation risk

Commercial presentations have historically included different strengths. A commonly cited tablet strength is approximately 25 mg orphenadrine citrate, 385 mg aspirin, and 30 mg caffeine, while higher-strength versions have also been marketed. The exact strength, label, manufacturer, and regulatory status must be evaluated product by product because historical brands and generic presentations have changed over time. [1]

The combination is generally administered as an immediate-release oral tablet. It is not a biologic, does not require biosimilar development, and is not dependent on a complex delivery device.

What excipient strategy is appropriate for this drug combination?

The preferred strategy is a low-moisture, immediate-release tablet platform that protects aspirin, maintains uniformity of the low-dose active ingredients, and produces an acceptable tablet size.

Recommended excipient architecture

Formulation function	Candidate excipient classes	Strategic purpose
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol	Controls tablet size, density, and compression
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Supports granule or tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Enables prompt immediate release
Lubricant	Magnesium stearate, sodium stearyl fumarate	Controls ejection and tooling friction
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Film coat	Hypromellose, polyvinyl alcohol, titanium dioxide, approved pigments	Improves appearance, handling, and swallowability
Moisture control	High-barrier blister, desiccant bottle, induction seal	Limits aspirin degradation during shelf life

A direct-compression formulation is commercially attractive because it reduces unit operations and avoids water exposure. The main technical risk is poor content uniformity caused by the relatively low amounts of orphenadrine citrate and caffeine compared with aspirin and the excipient mass.

A dry-granulation process can improve flow and reduce segregation without introducing aqueous moisture. Roller compaction is therefore a reasonable development option where direct compression does not meet blend-uniformity or tablet-strength targets.

Aqueous wet granulation is less attractive because aspirin can hydrolyze in the presence of moisture. If wet granulation is required, the process should minimize water exposure and include tight controls on granulation endpoint, drying temperature, residual moisture, and hold time.

Which excipients create the main compatibility risks?

Aspirin is the principal stability constraint. Hydrolysis can produce salicylic acid and acetic acid, particularly under elevated humidity or unsuitable processing conditions. The formulation should avoid unnecessary water, excessive heat, and excipient systems that increase local moisture activity.

Potential development risks include:

1. Moisture transfer from hygroscopic excipients.
2. Aspirin degradation during granulation or storage.
3. Segregation of low-dose orphenadrine citrate and caffeine.
4. Lubricant overmixing, which can slow dissolution.
5. Excessive tablet mass caused by the high aspirin load.
6. Anticholinergic-related patient complaints that may reduce adherence, even when the tablet is physically stable.

Excipient screening should include binary-mixture compatibility studies, accelerated stability, impurity profiling, dissolution testing after humidity exposure, and evaluation of packaging interaction.

What formulation patents could protect this combination?

The active-ingredient combination is old, so composition-of-matter protection is unlikely to provide a current commercial barrier. A new patent position would need to claim a specific and defensible technical feature.

Potential formulation claims could cover:

• A low-moisture tablet containing defined ratios of aspirin, orphenadrine citrate, and caffeine.
• A dry-granulated composition with specified residual-water limits.
• A coated tablet with improved aspirin stability.
• A formulation with reduced tablet mass or improved swallowability.
• A controlled-release dosage form with a defined release profile.
• A bilayer or multilayer tablet that separates incompatible ingredients.
• A unit-dose blister system that preserves assay and impurity specifications.
• A manufacturing process that reduces degradation or improves content uniformity.
• A formulation with a defined dissolution profile linked to a clinical or pharmacokinetic benefit.

A patent based only on replacing one conventional filler with another is vulnerable to obviousness challenges unless the formulation produces an unexpected stability, dissolution, manufacturing, or clinical result. Stronger claims would connect the excipient selection to measurable performance, such as lower salicylic-acid impurity, improved content uniformity, or longer shelf life under high-humidity conditions.

When does this product lose exclusivity?

The underlying product is an established small-molecule combination. Any original patents associated with early formulations or branded products are likely to have expired or become commercially irrelevant. The practical entry question is therefore regulatory rather than compound-patent driven.

Exclusivity category	Relevance to this combination
New chemical entity exclusivity	Not applicable to an old combination
Orphan-drug exclusivity	Not associated with the general musculoskeletal indication
Biologic exclusivity	Not applicable
Pediatric exclusivity	Product-specific and must be checked in FDA records
New formulation exclusivity	Possible only for a qualifying new product
Method-of-use patent	Possible but likely narrow and indication-specific
Listed Orange Book patent	Must be checked against the relevant reference product and current FDA listing

FDA Orange Book records, rather than historical marketing information, determine whether an active listed patent can delay an ANDA approval. [2] A product may be commercially discontinued while an old NDA remains relevant for reference-product purposes, so discontinued commercial sales do not by themselves resolve the regulatory pathway.

What is the Orange Book status of orphenadrine citrate, aspirin and caffeine?

The Orange Book analysis must be performed at the NDA and strength level. The relevant questions are:

• Which NDA is the reference product?
• Is the NDA currently approved, withdrawn, or listed as discontinued?
• Are any patents listed for the drug substance, formulation, or method of use?
• Are those patents expired, delisted, or subject to a statutory stay?
• Does the proposed generic match the reference product’s strength, dosage form, route, and labeling?

For an ANDA applicant, an absence of active listed patents would generally eliminate the need for a Paragraph IV certification. If an active patent is listed, the applicant may need a Paragraph III certification, a Paragraph IV certification, or a statement that the patent is not relevant to the proposed product.

A Paragraph IV challenge would be commercially meaningful only if a listed patent remains unexpired and covers the proposed product or an indication that the applicant seeks to include. The resulting litigation could create a 30-month stay under the Hatch-Waxman framework if the statutory conditions are met. [3]

What FDA regulatory pathway applies to a generic product?

A conventional generic would normally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product, together with adequate chemistry, manufacturing, and controls information.

Key development requirements include:

• Same active ingredients and dosage form as the reference product.
• Matching strength and route of administration.
• Comparable release characteristics.
• Validated assay and impurity methods.
• Stability data supporting the proposed shelf life.
• Content-uniformity data for orphenadrine citrate and caffeine.
• Packaging sufficient to control aspirin degradation.
• Labeling consistent with the approved reference product.

A 505(b)(2) application may be more appropriate for a genuinely differentiated product, such as a controlled-release formulation, a new dosage form, or a product requiring clinical data beyond ordinary bioequivalence. That route can create regulatory value, but it raises development cost and may generate new patent and exclusivity questions. [4]

How should manufacturers design the commercial formulation?

Immediate-release tablet opportunity

The lowest-risk commercial product is an immediate-release tablet that matches the established strength and labeling. The formulation target should prioritize:

• Small or moderate tablet size.
• Strong mechanical integrity.
• Rapid and reproducible disintegration.
• Dissolution comparable with the reference product.
• Low aspirin impurity growth.
• Reliable content uniformity.
• Low-cost, high-throughput compression.
• Standard film-coating equipment.

A high-dose aspirin component can make the tablet physically large. Partial use of high-density diluents, optimized compression, and a high-drug-load formulation can reduce tablet volume. A caplet shape and film coating may improve swallowability without changing the release profile.

Moisture-resistant presentation

A high-barrier blister may provide a stronger commercial proposition than a conventional high-density polyethylene bottle, particularly in humid markets. An aluminum-aluminum blister can reduce water-vapor transmission and provide unit-dose protection. A bottle remains attractive for lower packaging cost and high-volume dispensing, but it may require a desiccant and tighter closure specifications.

Modified-release opportunity

A controlled-release product could differentiate from a standard tablet, but it would require pharmacokinetic and clinical justification. Orphenadrine’s anticholinergic effects and the analgesic role of aspirin complicate release design. A modified-release product also creates a more demanding regulatory package and may not qualify as a simple ANDA.

Alternative dosage forms

Potential products include:

• Smaller-strength tablets for dose titration.
• Scored tablets where permitted by mechanical and regulatory testing.
• Oral powder or granule sachets.
• Dispersible tablets.
• Fixed-dose products with a more compact tablet architecture.

Liquid products face greater stability and taste challenges. Aspirin hydrolysis and the need to control suspension uniformity make an oral liquid less attractive unless it addresses a clear patient segment.

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barriers are process control and stability, not complex active-ingredient synthesis.

Barrier	Commercial effect	Mitigation
Aspirin hydrolysis	Shorter shelf life or impurity failures	Dry processing, low-moisture excipients, high-barrier packaging
Low-dose blend segregation	Content-uniformity failures	Particle-size engineering, ordered mixing, dry granulation
Large tablet mass	Poor patient acceptance	High-density excipients, caplet design, optimized dose architecture
Overlubrication	Slow dissolution	Controlled lubricant level and mixing time
Coating moisture	Stability risk	Low-water coating process and validated drying
Reference-product variability	Bioequivalence risk	Multiple development batches and discriminatory dissolution
Supplier concentration	Cost and continuity risk	Qualified alternate sources for critical excipients

The strongest patent opportunities are likely to relate to a technically distinctive process or delivery system rather than routine excipient substitution. A formulation patent should be supported by comparative data against both the unformulated actives and conventional generic formulations.

Which companies are challenging or competing with the product?

The competitive field is likely to consist of generic manufacturers, private-label suppliers, and companies marketing separate components rather than a large branded pharmaceutical company with an active innovation program.

Competition may come from:

1. Generic fixed-dose combination tablets.
2. Orphenadrine-only products.
3. Aspirin-containing analgesic combinations.
4. Caffeine-containing analgesic products.
5. Nonsteroidal anti-inflammatory drugs combined with muscle relaxants.
6. Centrally acting muscle relaxants such as cyclobenzaprine, methocarbamol, and tizanidine.

The combination’s commercial position is constrained by the availability of alternative treatment regimens and by safety considerations associated with aspirin and orphenadrine. Orphenadrine can cause dry mouth, blurred vision, urinary retention, constipation, and other anticholinergic effects. Aspirin creates gastrointestinal bleeding and salicylate-related risks. These factors limit broad substitution and make labeling, prescriber familiarity, and supply reliability important competitive variables.

What generic launch scenarios exist?

Scenario 1: Standard ANDA launch

This is the most practical route where the reference product, strength, and regulatory records are clear. The product competes primarily on price, availability, packaging, and wholesaler coverage.

Scenario 2: Authorized or licensed generic

A branded or reference-product owner could license manufacturing to a generic company. This may reduce development risk but requires access to the relevant regulatory file, manufacturing rights, or commercial agreement. No licensing arrangement should be assumed without a publicly documented agreement.

Scenario 3: Reformulated 505(b)(2) product

A smaller tablet, controlled-release version, or differentiated packaging system could support a 505(b)(2) strategy. The opportunity is larger if the product improves tolerability, adherence, or dosing convenience. The cost and regulatory risk are materially higher than for a standard ANDA.

Scenario 4: Geographic expansion

Markets with limited access to fixed-dose muscle-relaxant combinations may offer opportunities for local registration, contract manufacturing, or private-label supply. The commercial value depends on national aspirin restrictions, prescription classification, local bioequivalence rules, and the existence of competing orphenadrine products.

How strong is the patent estate for this combination?

The patent estate is likely weak for the basic active-ingredient combination and stronger only for a new formulation or manufacturing process with demonstrated technical advantages.

Patent subject	Expected strength
Basic combination of orphenadrine citrate, aspirin, and caffeine	Low
Conventional immediate-release tablet	Low
Defined low-moisture formulation with stability data	Moderate
Novel controlled-release system	Potentially moderate to strong
New indication or dosing regimen	Variable and clinically dependent
Packaging-only claims	Usually narrow
Manufacturing process that improves impurity control	Moderate if non-obvious and reproducible

Freedom-to-operate analysis should cover U.S. patents, European national rights, international filings, formulation patents, process patents, and any patent families assigned to current or former reference-product sponsors. Patent expiration must be determined from the specific patent family and jurisdiction rather than inferred from the age of the product.

What commercial opportunities are most attractive?

The most credible opportunities are:

• A low-cost, moisture-protected immediate-release generic.
• A smaller, easier-to-swallow tablet with equivalent release.
• A high-barrier blister product for humid climates.
• Reliable supply to institutional and specialty-pharmacy channels.
• Private-label or contract-manufactured versions.
• A differentiated 505(b)(2) formulation if clinical value can be demonstrated.
• Geographic licensing in markets where orphenadrine remains established.

Revenue exposure is likely modest relative to large analgesic or muscle-relaxant franchises because the product addresses a narrow prescription market and faces substitution from separate-component therapy. The opportunity is more suitable for a focused generic portfolio, contract manufacturer, or specialty pharmaceutical company than for a large-scale innovative-drug investment thesis.

Key Takeaways

• Aspirin stability and low-dose blend uniformity are the central formulation issues.
• Direct compression or dry granulation is preferable to aqueous wet granulation.
• High-barrier packaging can create a practical commercial advantage.
• The basic combination is unlikely to support meaningful new composition-of-matter exclusivity.
• A standard ANDA is the lowest-risk regulatory route for a matching immediate-release tablet.
• A 505(b)(2) product could create differentiation but would require greater clinical and regulatory investment.
• Paragraph IV risk depends on current Orange Book listings for the specific reference NDA, not on the product’s commercial history.
• Biosimilar risk is irrelevant because the product contains small-molecule active ingredients.
• The strongest intellectual-property opportunity is a validated formulation or manufacturing process that improves stability, dissolution, tablet size, or patient use.

FAQs

Is orphenadrine citrate, aspirin and caffeine an FDA-approved combination?

Historical U.S. products containing the combination have been marketed under prescription drug applications. Current approval, commercial availability, and generic status must be determined from the applicable FDA drug database and reference-product records.

Can aspirin be combined with orphenadrine in a moisture-sensitive tablet?

Yes. The formulation should use low-moisture processing, compatible excipients, controlled residual water, and packaging that limits water-vapor transmission.

Does this product have biosimilar competition?

No. Orphenadrine citrate, aspirin, and caffeine are chemically synthesized small molecules. Competition proceeds through generic-drug pathways rather than biosimilar pathways.

Would an enteric-coated version have commercial value?

Potentially, but an enteric-coated product would change the release profile and could require a different regulatory strategy. It would need a clear clinical or tolerability rationale and comparative release data.

Can a new excipient combination receive a patent?

Yes, if the formulation is novel, non-obvious, adequately described, and supported by evidence of a technical effect. Routine substitution of standard fillers or disintegrants is unlikely to provide durable protection by itself.

References

1. DailyMed. (n.d.). Orphenadrine citrate, aspirin, and caffeine tablet labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
4. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applications-covered-section-505b2-0-federal-food-drug-and-cosmetic-act